Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus

What Was Tested

This clinical trial paper looks at Amylin (Islet Amyloid Polypeptide).

The purpose of this study was to determine the effect of adjuvant premeal pramlintide with postmeal insulin on postprandial hyperglycemia in children with type 1 diabetes mellitus (T1DM).

Who Took Part

The age groups tagged for this paper are children and teenagers, both men and women.

Eight adolescents with T1DM on intensive insulin therapy participated in an open-label, non-randomized, crossover study, comparing postprandial glucose excursions in study A (prescribed insulin regimen and given premeal) vs. study B (pramlintide + insulin).

How the Study Was Run

The design is described as open-label and crossover.

Everyone knew when Amylin (Islet Amyloid Polypeptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

In the crossover set-up each of the participants took both Amylin (Islet Amyloid Polypeptide) and the comparison in turn, acting as their own control.

Blood glucose (BG), glucagon, and pramlintide concentrations were measured basally and at timed intervals during a 300-min study period.

What Was Measured

PubMed files the paper under topics including Amyloid, Chemotherapy, Adjuvant, Diabetes Mellitus, Type 1, Feeding Behavior, Glucagon, Hyperglycemia and Hypoglycemic Agents.

What This Means in Plain Language

The paper is an open-label and crossover study of Amylin (Islet Amyloid Polypeptide).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2009 (Pediatric diabetes), a journal based in China.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.